Full-Time

Senior Clinical Lead

Early Clinical & Experimental Therapeutics

Deadline 9/25/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

Compensation Overview

$236.3k - $393.8k/yr

Cambridge, MA, USA + 1 more

More locations: Morristown, NJ, USA

Hybrid

Hybrid role; required office days are not stated.

PhD, MD

Category
Biology & Biotech (2)
,
Required Skills
Biostatistics
Pharmacology

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • An M.D. or M.D./Ph.D. advanced degree is required.
  • At least 3 years of clinical research experience is required, including oversight of patients on early Phase 1/2a clinical trials and interpretation of preclinical and biomarker data.
  • Experience designing and executing early development clinical trials, including Phase 1/2a and exploratory studies, in pharmaceutical industry, academia, hospitals, clinical sites, or contract research organizations is required.
  • Experience leading cross-functional teams is required.
  • Experience providing medical safety oversight for clinical trials is required.
  • Experience participating in the design or interpretation of translational or biomarker research is required.
  • Experience using emerging digital or artificial-intelligence-driven tools and solutions is required.
  • Broad biomedical knowledge applied to the design and interpretation of nonclinical and clinical experiments is required.
  • Knowledge of good clinical practice is required.
  • Ability to acquire and apply new technical skills is required.
  • Excellent verbal and written communication skills for global interactions across functional areas, contract research organizations, and regulatory agencies are required.
  • Capability to challenge decisions and the status quo using a risk-management approach is required.
  • Ability to work within a matrix organization is required.
  • International and intercultural working skills are required.
  • Ability to prepare and distribute the Key Results Memo and prepare or review the Clinical Study Report is required.
  • English language proficiency is required.
Responsibilities
  • Design safe, rapid, and informative First-in-Human studies for oncology assets, potentially including natural history, experimental model validation, mechanistic and signal-seeking studies, streamlined Proof-of-Mechanism and Proof-of-Concept studies, and pharmacokinetic studies.
  • Participate in designing the plans for the different steps of clinical development and integrate them into the overall development strategy with the responsible therapeutic areas in research and development.
  • Provide medical and clinical expertise to guide strategy for preclinical data generation and interpretation for oncology assets.
  • Make front-line decisions on protocol design, execution, dose escalation, safety, and information for regulatory authorities.
  • Supervise the successful execution of clinical studies.
  • Oversee and perform medical monitoring.
  • Review and interpret results and author clinical documentation, including informed consent forms, clinical protocols, study reports, abstracts or manuscripts, clinical pharmacology or experimental therapeutics components of investigator brochures, and regulatory documents.
  • Interact with managers from various disciplines, serve as an expert and internal consultant on the assigned area, and liaise with project partners.
  • Participate in dose selection for First-in-Human studies and drive Go or No-Go decisions when needed.
  • Ensure adequate follow-up of studies and project timelines.
  • Ensure clinical trial standards are maintained at sites and in cooperation with other clinical functions.
  • Ensure high-quality documents and implement an appropriate communication process.
  • Manage aggressive timelines through cross-functional planning.
  • Maintain effective collaborations with investigators and external experts.
  • Present data at appropriate internal or external meetings.
  • Design and conduct early clinical development studies from First-in-Human through Phase 2a within planned timelines with operational-team support.
  • Review and approve study documentation, including monitoring plans, statistical analysis plans, contracts, and regulatory documents.
  • Coordinate the clinical team to set up and follow studies.
  • Ensure proper documentation is provided to ethics committees and health authorities.
  • Ensure studies are scientifically sound and correctly conducted.
  • Coordinate oversight of contract research organizations and outsourced activities.
  • Coordinate cross-functional communication and cooperation.
  • Prepare and review interim investigator reports.
  • Lead dose-escalation meetings and document decision-making for First-in-Human studies.
  • Review adverse-event reports and oversee safety monitoring.
  • Participate in data review and validation meetings before database lock.
  • Review and interpret study results.
  • Prepare and distribute the Key Results Memo and prepare or review the Clinical Study Report.
Desired Qualifications
  • MD plus PhD or analogous bench-science experience is strongly preferred.
  • Experience in a global pharmaceutical setting is preferred.
  • Medical or scientific experience with combination therapies and drugs targeting cytoplasmic signaling pathways is preferred.
  • Postgraduate residency training and laboratory research experience in industry or academia is preferred.
  • Experience conducting late-phase clinical trials is preferred.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 17.8%; Dupixent topped €5.2 billion for the quarter.
  • July 30 upgraded 2026 guidance to around 10% sales growth, with higher EPS.
  • August 4 MenQuadfi infant approval widens vaccine reach; Nexviazyme's June phase 3 readout strengthens pipeline.

What critics are saying

  • Dupixent faces tougher H2 2026 comparisons, threatening growth after the €5.2 billion quarter.
  • Cenrifki carries liver injury risk; strict monitoring can slow adoption and invite liability.
  • Dupixent concentration and Regeneron's November 2024 lawsuit threaten Sanofi's core growth engine.

What makes Sanofi unique

  • Dupixent and partnered launch engine generate repeatable immunology cash flows across geographies.
  • Sanofi converted 2026 approvals for Sarclisa Escena, Wayrilz, and Cenrifki into launches.
  • Paulo Fontoura's September 1 R&D mandate centralizes translational science and regulatory execution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.

Associated Press
Jul 10th, 2026
Sanofi's Sarclisa Escena approved in US as first anticancer drug delivered via on-body injector

The US Food and Drug Administration has approved Sanofi's subcutaneous Sarclisa Escena for treating multiple myeloma, making it the first anticancer treatment administered through an on-body injector. The therapy uses Enable Injections' CirCLIQ device, which delivers the drug automatically with a retractable 30g needle. The approval was supported by the IRAKLIA phase 3 study, which demonstrated that Sarclisa Escena delivered via the on-body injector provided similar efficacy and safety compared to intravenous infusion, with significantly shorter treatment time and fewer infusion-related reactions. The study showed a 71.1% objective response rate in patients with relapsed or refractory multiple myeloma. More than 70,000 patients worldwide have been treated with Sarclisa-based regimens. The on-body injector aims to reduce physical burden on healthcare providers whilst offering patients greater convenience during treatment.

Yahoo Finance
Jul 5th, 2026
Sanofi appoints Paulo Fontoura as R&D chief to accelerate pharma pipeline transformation

Sanofi has appointed Paulo Fontoura as Executive Vice President and Global Head of Research & Development Pharma, effective 1 September. Based in Paris, Fontoura will oversee the company's innovation engine, spanning research, translational medicine, clinical development, and regulatory affairs. He succeeds Dr Houman Ashrafian, who is leaving to pursue new opportunities. Fontoura brings over 25 years of experience across academic medicine, translational science, and pharmaceutical innovation. The appointment comes as Sanofi drives an R&D transformation whilst progressing its pipeline across multiple therapeutic areas. Separately, MacroGenics confirmed it will receive $24.5 million in regulatory milestone payments from Sanofi following FDA accelerated approval of TZIELD to delay decline in endogenous insulin production in children. Sanofi is a global biopharmaceutical company focusing on immunology, rare diseases, and oncology.